Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CETP | P11597 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891618 | 1.00 | SPHK1 (0.61) | SPHK1CYP2D6TP53LMNAGMNN | |
| SCHEMBL3786621 | 1.00 | SPHK1 (0.61) | SPHK1CYP2D6TP53LMNAGMNN | |
| SCHEMBL8369324 | 1.00 | SPHK1 (0.61) | SPHK1CYP2D6TP53LMNAGMNN | |
| SCHEMBL460570 | 1.00 | SPHK1 (0.61) | SPHK1CYP2D6TP53LMNAGMNN | |
| Hydrochloric Acid SCHEMBL11461378 | 0.98 | SPHK1 (0.59) | SPHK1CYP2D6TP53LMNAGMNN | |
| Hydrochloric Acid SCHEMBL11187511 | 0.98 | SPHK1 (0.59) | SPHK1CYP2D6TP53LMNAGMNN | |
| SCHEMBL6157769 | 0.98 | SPHK1 (0.58) | SPHK1CYP2D6TP53LMNAGMNN | |
| SCHEMBL18923235 | 0.90 | — | — | |
| SCHEMBL15241781 | 0.90 | — | — | |
| SCHEMBL18109589 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| EP-2389436-A2 | STEM CELL CULTURE METHODS | ITI Scotland Limited (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257911-A1 | SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING | JOHNSON CONTROLS TECHNOLOGY COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2010084300-A2 | STEM CELL CULTURE METHODS | ITI SCOTLAND LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
| EP-0287696-B1 | ISOQUINOLINE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-01-02 | — | — | EP | disclosed |
| EP-0287696-A1 | Isoquinoline derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4602089-A | Process for preparing purine compounds | NEWPORT PHARMACEUTICALS, INC. (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0126813-A1 | Process for preparing imidazole compounds | Newport Pharmaceuticals International, Inc. (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4451478-A | IMMUNOLOGY, ACTIVATORS | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1984-05-29 | — | — | US | disclosed |
| US-4432990-A | ANTIBODY INHIBITORS, ANTIALLERGENS, ANTITUMOR, ANTIULCER, AND ANTIARTHRITIC AGENTS | FISONS PLC (GB) | 1984-02-21 | — | — | US | disclosed |
| EP-0066909-A2 | Imidazole derivatives, pharmaceutical compositions containing them and processes for their production | FISONS plc (GB) | 1982-12-15 | — | — | EP | disclosed |
| EP-0009154-B1 | COMPLEXES OF 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITIONS CONTAINING THE COMPLEXES AS ACTIVE INGREDIENTS | Newport Pharmaceuticals International, Inc. (US) | 1982-12-08 | — | — | EP | disclosed |
| EP-0009155-B1 | 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITION CONTAINING THE 9-HYDROXYALKYL-PURINES AS ACTIVE INGREDIENTS | Newport Pharmaceuticals International, Inc. (US) | 1982-11-17 | — | — | EP | disclosed |
| US-4315920-A | Adenosine deaminase inhibitors | BURROUGHS WELLCOME CO. (US) | 1982-02-16 | — | — | US | disclosed |
| US-4221909-A | P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-09-09 | — | — | US | disclosed |
| US-4221794-A | Method of imparting immunomodulating and antiviral activity | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4221910-A | IMMUNOPOTENTIATORS, VIRICIDES, ANTILEUKEMIA AGENTS | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| EP-0009155-A1 | 9-Hydroxyalkyl-purines, processes for preparing them and therapeutical composition containing the 9-hydroxyalkyl-purines as active ingredients | Newport Pharmaceuticals International, Inc. (US) | 1980-04-02 | — | — | EP | disclosed |
| EP-0009154-A1 | Complexes of 9-hydroxyalkyl-purines, processes for preparing them and therapeutical compositions containing the complexes as active ingredients | Newport Pharmaceuticals International, Inc. (US) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | SPHK1 3188/4885CYP2D6 4131/4885TP53 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.